Develops topical drug candidates for patients with serious, rare skin diseases and vascular malformations.
10-K for FY2025, filed Mar 31, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$24.6MView ↗
8-K, filed Aug 4, 2026
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA…View ↗
From Anticalin to QTORIN
The older report centered on Anticalin protein drugs for respiratory and cancer-related conditions, with several programs developed alongside pharmaceutical partners. The latest report instead focuses on topical QTORIN candidates for rare skin diseases and vascular malformations, with plans to develop and, if approved, commercialize them.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026
Competes with Kaken Pharmaceutical, Nobelpharma, Novartis Pharmaceuticals, Protara Therapeutics, Relay Therapeutics, Vaderis Therapeutics, and Quoin Pharmaceuticals
10-K for FY2025, filed Mar 31, 2026The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong…View ↗
Loading...